Cabozantinib Effective in Treating Metastatic Kidney Cancer by Angela Mohan on February 15, 2021 at 3:21 PM
Cabozantinib was found most effective in treating patients with metastatic papillary kidney cancer, as per results of a SWOG Cancer Research Network trial.
These findings will be presented at ASCO s virtual 2021 Genitourinary Cancers Symposium 2021. The findings will be simultaneously published in
The Lancet.
There are currently no effective treatments for metastatic papillary kidney cancer, or metastatic pRCC, a rare subtype of kidney cancer. One study of 38 patients found that the average survival rate was eight months after diagnosis.
Sumanta Pal, MD, clinical professor of medical oncology at City of Hope, a comprehensive cancer center, and an investigator at SWOG, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), said there is hope for metastatic papillary kidney cance